Literature DB >> 20425521

Drug-related myopathies of which the clinician should be aware.

Ritu Valiyil1, Lisa Christopher-Stine.   

Abstract

Many drugs used for therapeutic interventions can cause unanticipated toxicity in muscle tissue, often leading to considerable morbidity. A drug-induced, or toxic, myopathy is defined as the acute or subacute manifestation of myopathic symptoms such as muscle weakness, myalgia, creatine kinase elevation, or myoglobinuria that can occur in patients without muscle disease when they are exposed to certain drugs. A brief review of agents with a known association with myotoxicity and the proposed mechanisms linked to that toxicity is outlined; however, the purpose of this review is to highlight recent discoveries and advances in the field of toxic myopathies that have practical implications for practicing physicians. Because many drug-related myopathies are potentially reversible at early stages, it is important for clinicians to recognize toxic myopathies early in their course to determine when to discontinue therapy and potentially prevent irreversible muscle damage.

Entities:  

Mesh:

Year:  2010        PMID: 20425521      PMCID: PMC3092639          DOI: 10.1007/s11926-010-0104-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  48 in total

1.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

2.  Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma.

Authors:  R A Covar; D Y Leung; D McCormick; J Steelman; P Zeitler; J D Spahn
Journal:  J Allergy Clin Immunol       Date:  2000-10       Impact factor: 10.793

3.  Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.

Authors:  James M Backes; Carmelo V Venero; Cheryl A Gibson; Janelle F Ruisinger; Patricia A Howard; Paul D Thompson; Patrick M Moriarty
Journal:  Ann Pharmacother       Date:  2008-02-19       Impact factor: 3.154

Review 4.  Drug-induced myopathies.

Authors:  Thomas Klopstock
Journal:  Curr Opin Neurol       Date:  2008-10       Impact factor: 5.710

Review 5.  Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2008-06       Impact factor: 7.616

Review 6.  Ezetimibe-associated adverse effects: what the clinician needs to know.

Authors:  M Florentin; E N Liberopoulos; M S Elisaf
Journal:  Int J Clin Pract       Date:  2008-01       Impact factor: 2.503

7.  Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.

Authors:  Joaquín Hinojosa; Joaquín Borrás-Blasco; Nuria Maroto; J Dolores Rosique-Robles; Rafael Alos; Md Elvira Casterá
Journal:  Ann Pharmacother       Date:  2008-05-20       Impact factor: 3.154

8.  Statin-associated myopathy with normal creatine kinase levels.

Authors:  Paul S Phillips; Richard H Haas; Sergei Bannykh; Stephanie Hathaway; Nancy L Gray; Bruce J Kimura; Georgirene D Vladutiu; John D F England
Journal:  Ann Intern Med       Date:  2002-10-01       Impact factor: 25.391

9.  Chronic progressive external ophthalmoplegia.

Authors:  G Danta; R C Hilton; P G Lynch
Journal:  Brain       Date:  1975-09       Impact factor: 13.501

10.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

View more
  29 in total

1.  Modeling the Effect of TNF-α upon Drug-Induced Toxicity in Human, Tissue-Engineered Myobundles.

Authors:  Brittany N J Davis; Jeffrey W Santoso; Michaela J Walker; Catherine E Oliver; Michael M Cunningham; Christian A Boehm; Danielle Dawes; Samantha L Lasater; Kim Huffman; William E Kraus; George A Truskey
Journal:  Ann Biomed Eng       Date:  2019-04-08       Impact factor: 3.934

2.  New perspectives on dry needling following a medical model: are we screening our patients sufficiently?

Authors:  Gary Kearns; César Fernández-De-Las-Peñas; Jean-Michel Brismée; Josué Gan; Jacqueline Doidge
Journal:  J Man Manip Ther       Date:  2019-01-19

3.  Drug-induced myopathy in a patient with pulmonary tuberculosis.

Authors:  Rajiv Shah; Pradhib Venkatesan
Journal:  BMJ Case Rep       Date:  2015-07-15

4.  Diagnosis and treatment of inflammatory myopathy: issues and management.

Authors:  Christine Castro; Mark Gourley
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

5.  Safety of olmesartan in a patient with telmisartan-induced myotoxicity: a case report.

Authors:  Manish J Barvaliya; Viren N Naik; Ashok C Shah; Chandrabhanu R Tripathi
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

6.  A super-combo-drug test to detect adverse drug events and drug interactions from electronic health records in the era of polypharmacy.

Authors:  Anqi Zhu; Donglin Zeng; Li Shen; Xia Ning; Lang Li; Pengyue Zhang
Journal:  Stat Med       Date:  2020-02-26       Impact factor: 2.373

Review 7.  ERS International Congress 2017: a peek of outstanding abstracts from the clinical assembly.

Authors:  Nicolas Kahn; Vasileios Andrianopoulos; Evgeni Mekov; Felix J F Herth
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

8.  Human, Tissue-Engineered, Skeletal Muscle Myobundles to Measure Oxygen Uptake and Assess Mitochondrial Toxicity.

Authors:  Brittany N J Davis; Jeffrey W Santoso; Michaela J Walker; Cindy S Cheng; Timothy R Koves; William E Kraus; George A Truskey
Journal:  Tissue Eng Part C Methods       Date:  2017-03-24       Impact factor: 3.056

Review 9.  Update on toxic myopathies.

Authors:  F L Mastaglia; M Needham
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

10.  The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis.

Authors:  Zhen Zhou; Loai Albarqouni; Andrea J Curtis; Monique Breslin; Mark Nelson
Journal:  Drugs Aging       Date:  2020-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.